Type
Competitive ELISA
Description
SARS-CoV-2 Spike-ACE2 Binding Assay is a quantitative competitive ELISA kit that is designed to measure the interaction between the receptor binding domain of the viral spike glycoprotein (S1RBD) with the cell surface receptor ACE2. The assay can detect and quantify the neutralizing antibodies in human plasma or serum.
Applications
Serum, Plasma, Others, COVID-19
Shipping
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Storage/Expiration
The kit should be stored at 2–8°C. Under these conditions, all components are stable until the expiration date (see label on the box). All reagents should be equilibrated to room temperature before use. Immediately after use remaining reagents should be returned to cold storage (2–8°C). Once opened, the strips may be stored at 2–8°C for up to one month.
Note
The kits are CE-IVD certified and intended for professional use.
Features
For Research Use Only. Not for diagnostic procedures.
The assay can detect and quantify the neutralizing antibodies in human plasma or serum which inhibit the S1RBD-ACE2 interaction.
Standard solution: Calibrated with WHO International Standard for anti-SARS-CoV-2 immunoglobulin, NIBSC code:20/136, 22 ul, 1000 IU/ml.
The total assay time is less than 2.5 hours.
Assay format is 96 wells.
Research topic
COVID-19
Summary
The ongoing global pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). SARS-CoV-2 is an enveloped virus with a positive-sense RNA genome and a nucleocapsid of helical symmetry. The SARS-CoV-2 entry into host cells is mediated by the transmembrane spike (S) glycoprotein, which contains a receptor binding domain (RBD). S1RBD is responsible for binding with angiotensin converting enzyme-2 (ACE2), leading to endocytosis into the host cells and viral replication. S1RBD is the main target of neutralizing antibodies upon infection and the focus of the therapeutic drug and vaccine design. Molecules that inhibit formation of the S1RBD-ACE2 complex in vitro could be potential treatment for COVID-19 infection.
The SARS-COV-2 Spike-ACE2 Binding Assay is designed to measure the interaction between the receptor binding domain of the viral spike glycoprotein (S1RBD) with the cell surface receptor ACE2. The assay can detect and quantify the neutralizing antibodies in human plasma or serum which inhibit the S1RBD-ACE2 interaction, and can also be used for screening the inhibitors and potential drug and vaccine development.
Instructions for Use (RUO)
Instructions for Use (RUO)
Find documents for the lot
